Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M116,161Revenue $M45,698Net Margin (%)20.5Z-Score2.4
Enterprise Value $M142,087EPS $3.8Operating Margin %26.5F-Score7
P/E(ttm))14.8Cash Flow Per Share $4.7Pre-tax Margin (%)25.1Higher ROA y-yY
Price/Book11.510-y EBITDA Growth Rate %3.1Quick Ratio0.8Cash flow > EarningsY
Price/Sales2.85-y EBITDA Growth Rate %2.4Current Ratio1.1Lower Leverage y-yY
Price/Cash Flow9.3y-y EBITDA Growth Rate %-10.7ROA % (ttm)12.9Higher Current Ratio y-yY
Dividend Yield %5.3Insider Buy (3m)0ROE % (ttm)77.7Less Shares Outstanding y-yY
Payout Ratio %81.0Shares Outstanding M2,427ROI % (ttm)14.0Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKJohn Hussman 2014-03-31 Reduce-0.38%$50.9 - $56.66
($54)
$ 48.03-11%Reduce -23.61%323,500
GSKVanguard Health Care Fund 2014-03-31 Sold Out -0.11%$50.9 - $56.66
($54)
$ 48.03-11%Sold Out0
GSKJohn Hussman 2013-12-31 Add1.51%$49.31 - $53.68
($51.87)
$ 48.03-7%Add 1702.13%423,500
GSKCharles Brandes 2013-12-31 Add0.16%$49.31 - $53.68
($51.87)
$ 48.03-7%Add 13.11%2,145,461
GSKJoel Greenblatt 2013-12-31 Buy 0.11%$49.31 - $53.68
($51.87)
$ 48.03-7%New holding, 83452 sh.83,452
GSKVanguard Health Care Fund 2013-12-31 Reduce-0.14%$49.31 - $53.68
($51.87)
$ 48.03-7%Reduce -55.18%644,881
GSKWarren Buffett 2013-12-31 Sold Out -0.02%$49.31 - $53.68
($51.87)
$ 48.03-7%Sold Out0
GSKWarren Buffett 2013-09-30 Reduce-0.06%$50.27 - $52.96
($51.54)
$ 48.03-7%Reduce -76.57%345,819
GSKJoel Greenblatt 2013-06-30 Sold Out -0.16%$46.79 - $53.59
($50.77)
$ 48.03-5%Sold Out0
GSKVanguard Health Care Fund 2013-06-30 Reduce-0.1%$46.79 - $53.59
($50.77)
$ 48.03-5%Reduce -26.11%1,611,181
GSKJean-Marie Eveillard 2013-06-30 Reduce-0.05%$46.79 - $53.59
($50.77)
$ 48.03-5%Reduce -100%1
GSKJohn Hussman 2013-03-31 Reduce-0.57%$43.47 - $46.91
($44.97)
$ 48.037%Reduce -95.51%23,500
GSKVanguard Health Care Fund 2013-03-31 Reduce-0.07%$43.47 - $46.91
($44.97)
$ 48.037%Reduce -20.49%2,180,381
GSKJohn Hussman 2012-12-31 Add0.58%$41.9 - $47.45
($44.3)
$ 48.038%Add 2584.62%523,500
GSKDodge & Cox 2012-12-31 Add0.18%$41.9 - $47.45
($44.3)
$ 48.038%Add 5.08%63,302,825
GSKTweedy Browne 2012-12-31 Add0.03%$41.9 - $47.45
($44.3)
$ 48.038%Add 20.16%151,264
GSKJoel Greenblatt 2012-12-31 Reduce-0.09%$41.9 - $47.45
($44.3)
$ 48.038%Reduce -32.53%60,720
GSKJoel Greenblatt 2012-09-30 Buy 0.28%$44.25 - $47.23
($46.06)
$ 48.034%New holding, 89990 sh.89,990
GSKJean-Marie Eveillard 2012-03-31 Buy 0.06%$43.73 - $46.35
($42.21)
$ 48.0314%New holding, 322701 sh.322,701
GSKCharles Brandes 2011-12-31 Reduce-0.3%$40.53 - $45.74
($44)
$ 48.039%Reduce -20.33%3,035,713
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GSK Charles Brandes 2014-03-312,164,2410.091.5+0.88%
GSK Jean-Marie Eveillard 2014-03-31100
GSK Joel Greenblatt 2014-03-3183,45200.07
GSK Dodge & Cox 2014-03-3160,386,5502.493.3-0.15%
GSK Tweedy Browne 2014-03-31142,5980.010.18-5.05%
GSK PRIMECAP Management 2014-03-319,177,8770.380.56-8.21%
GSK John Hussman 2014-03-31323,5000.011.3-23.61%
GSK Vanguard Health Care Fund 2014-03-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12301.5view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14244.14view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12301.5view

Press Releases about GSK :

    Quarterly/Annual Reports about GSK:

      News about gsk:

      Articles On GuruFocus.com
      A Look at the Week's Top Dividend Growers Jul 28 2014 
      Highest Yielding Stocks Widely Held By The Gurus Jul 01 2014 
      Diamond Hill Capital Comments on GlaxoSmithKline PLC Jun 26 2014 
      Major British Companies Lead Top Guru-Held UK and Ireland Stocks Jun 10 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 
      Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 
      Weekly 52-Week Highs Highlight: AV, XEL, OKE, GSK Apr 28 2014 
      These Three Pharmaceutical Companies Shake The Market With Their Deal Apr 27 2014 
      GlaxoSmithKline Finally Received Approval from FDA for Its Diabetes Drug Tanzeum (Albiglutide) Apr 19 2014 
      Why Buy-and-Hold-Forever Buffett’s Company Just Sold Two Stocks Feb 27 2014 


      More From Other Websites
      What You Were Buying Last Week: GlaxoSmithKline plc Jul 29 2014
      [$$] Investigators Tied to GSK Get Trial Date Jul 28 2014
      Will GlaxoSmithKline plc Split Itself In Two? Jul 28 2014
      Will GlaxoSmithKline plc Split Itself In Two? Jul 28 2014
      Glaxo Has No Plans to Spin Off Consumer Health-Care Division Jul 28 2014
      GSK Boss Says Pharma Giant May Be Split Up Jul 28 2014
      The FTSE 100′s Hottest Dividend Picks: GlaxoSmithKline plc Jul 28 2014
      The FTSE 100's Hottest Dividend Picks: GlaxoSmithKline plc Jul 28 2014
      3 Shares That Can Benefit From A Resurgent UK Economy Jul 25 2014
      Baksheesh? Glaxo Allegedly Paid Bribes in Syria, too, a Report Says Jul 25 2014
      Glaxo Files Its Entry in Race for a Malaria Vaccine Jul 25 2014
      The Buy Case For GlaxoSmithKline plc Is Getting Stronger Every Day Jul 25 2014
      The Buy Case For GlaxoSmithKline plc Is Getting Stronger Every Day Jul 25 2014
      Glaxo Investigates Allegations of Bribery in Syria Jul 25 2014
      UCB's Brivaracetam Positive in Phase III Epilepsy Study Jul 24 2014
      GlaxoSmithKline Jul 24 2014
      Can GlaxoSmithKline’s Slumping Stock Recover? Jul 24 2014
      FDA approves Flonase allergy relief for sale over-the-counter in the United States Jul 24 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide